# BiomX

BiomX is an Asset Manager based in Ness Ziona, Israel.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Ness Ziona, Israel
- **Region:** Middle East
- **Address:** Ness Ziona, Israel
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** biomx.com
- **LinkedIn:** https://www.linkedin.com/company/biomx

## Regulatory record

- **Reports private funds:** No

## About

BiomX is a biotechnology firm based in Ness Ziona, Israel, established in 2015. It develops customized phage therapies to target harmful bacteria in chronic diseases. The company has secured $113.48 million in total funding.

## Sectors

- Biotechnology
- Healthcare Services

## People

- Jonathan Solomon — Chief Executive Officer

## Questions

### Who runs investment and strategic decisions at BiomX?

Jonathan Solomon has served as Chief Executive Officer since the company's founding in 2015, steering its evolution from a Weizmann Institute spinout to a publicly traded entity on the NYSE. Strategic decisions, including the March 2024 merger with Adaptive Phage Therapeutics, are executed by the executive leadership team under board oversight. The board includes representatives from both the legacy BiomX and post-merger APT shareholder bases.

### How does BiomX fund its development pipeline?

BiomX funds operations through a combination of public equity, development grants, and strategic partnerships. Its 2019 NYSE listing via a SPAC merger provided initial public capital, followed by periodic registered direct offerings. The Cystic Fibrosis Foundation committed $5 million to the BX004 clinical program in 2021. The March 2024 merger with Adaptive Phage Therapeutics was structured as an all-stock transaction, bringing APT's pipeline into the combined entity while APT shareholders received a majority equity stake.

### What therapeutic areas does BiomX target?

BiomX concentrates on chronic diseases where a specific, identifiable bacterial pathogen drives disease progression. Its lead program targets Pseudomonas aeruginosa infections in cystic fibrosis patients, while a dermatology subsidiary addresses Cutibacterium acnes in acne vulgaris. Following the 2024 APT merger, the pipeline expanded to include prosthetic joint infections and recurrent urinary tract infections, both associated with well-characterized bacterial strains amenable to phage targeting.

## Related profiles

- [Haemonetics](https://altss.com/profile/haemonetics-corporation)

---

Last updated: 2026-05-30T21:19:41.177Z

Canonical page: https://altss.com/profile/biomx-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology